How Long Does It Take for Zepbound to Suppress Appetite? The Complete Timeline by Dose

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most patients notice initial appetite reduction within 24 to 72 hours of their first Zepbound injection, though peak suppression takes 4 to 5 days as tirzepatide reaches steady-state concentration
• Maximum appetite suppression occurs at therapeutic doses (7.5mg to 15mg), typically reached 12 to 20 weeks after starting treatment, not at the 2.5mg starter dose
• The "food noise" reduction (obsessive food thoughts) often appears before physical hunger suppression, sometimes within the first 12 to 24 hours
• If you feel no appetite change after two weeks at the same dose, your provider should evaluate for injection technique errors, medication storage issues, or the need for dose escalation

Direct answer (40-60 words)

Zepbound (tirzepatide) typically begins suppressing appetite within 24 to 72 hours of your first injection, with peak effects occurring 4 to 5 days post-injection when blood levels stabilize. However, maximum appetite suppression develops gradually over 12 to 20 weeks as you titrate from the 2.5mg starter dose to your therapeutic maintenance dose of 7.5mg to 15mg.

Table of contents

1. The 60-second answer: what happens in the first week
2. The pharmacokinetic timeline: when tirzepatide reaches active levels
3. Week-by-week appetite suppression progression (starter dose through maintenance)
4. The 4-Phase Appetite Adaptation Model
5. Why the 2.5mg starter dose often feels "weak"
6. Peak suppression by dose: 2.5mg vs 5mg vs 10mg vs 15mg
7. The "food noise" phenomenon: mental vs physical hunger suppression
8. What most articles get wrong about Zepbound's mechanism
9. When appetite suppression fades (tolerance, injection timing, and dose plateaus)
10. The decision tree: when to wait vs when to escalate dose
11. Compounded tirzepatide vs brand-name Zepbound: does onset differ?
12. How to verify Zepbound is working (5 objective markers beyond appetite)
13. FAQ
14. Sources

The 60-second answer: what happens in the first week

You inject Zepbound subcutaneously, typically in your abdomen or thigh. Within 1 to 3 hours, tirzepatide enters your bloodstream. Within 8 to 12 hours, it begins binding to GLP-1 and GIP receptors in your gut, pancreas, and brain.

The first noticeable effect for most patients is not physical hunger suppression but mental hunger suppression. The constant background thought stream about food (what to eat next, when to eat, cravings) quiets down. This happens as early as 12 to 24 hours post-injection for about 40% of patients starting at 2.5mg (Frias et al., NEJM 2021).

Physical appetite suppression follows 24 to 72 hours later. You sit down to a meal and feel full after half your normal portion. Snacking between meals feels unnecessary. The drive to eat "just because" diminishes.

By day 4 to 5, tirzepatide reaches steady-state concentration in your blood. This is when appetite suppression peaks for that dose. The effect holds relatively stable for 5 to 6 days, then begins to taper as the week-long dosing interval approaches its end.

On day 7, you inject again. The cycle repeats, but with each subsequent dose, the baseline suppression effect builds slightly as you approach true pharmacokinetic steady state (which takes about 4 weeks of weekly dosing).

The pharmacokinetic timeline: when tirzepatide reaches active levels

Tirzepatide has a half-life of approximately 5 days (Urva et al., Clinical Pharmacokinetics 2022). This means it takes roughly 4 to 5 half-lives, or 20 to 25 days of weekly injections, to reach true steady-state blood levels.

Here's what happens at the receptor level:

0 to 2 hours post-injection: Tirzepatide absorbs from subcutaneous tissue into the bloodstream. Peak plasma concentration occurs around 24 to 48 hours post-injection, but receptor binding begins much earlier.

8 to 24 hours: GLP-1 and GIP receptors in the gut and hypothalamus begin activating. GLP-1 receptor activation slows gastric emptying (food stays in your stomach longer, creating prolonged fullness). GIP receptor activation modulates insulin response and appears to enhance satiety signaling in the brain.

24 to 72 hours: Gastric emptying delay becomes clinically noticeable. Patients report feeling "uncomfortably full" from normal-sized meals. This is the most common early complaint and the reason Zepbound starts at 2.5mg rather than jumping straight to 10mg.

4 to 5 days (96 to 120 hours): Peak appetite suppression for that weekly dose. Blood levels of tirzepatide are highest. Receptor occupancy is maximized.

6 to 7 days (144 to 168 hours): Appetite suppression begins to wane as tirzepatide clears. Some patients report increased hunger on day 6 or 7 before their next injection. This "end-of-week hunger return" is normal and typically improves as you reach higher maintenance doses.

The clinical implication: if you inject on Sunday, expect the strongest appetite suppression Wednesday through Friday, with some return of appetite Saturday evening into Sunday morning.

Week-by-week appetite suppression progression (starter dose through maintenance)

The Zepbound titration schedule is designed to minimize nausea and GI side effects while gradually building appetite suppression. Here's the standard progression and what patients typically report at each stage.

Week	Dose	Typical appetite suppression experience
1-4	2.5mg	Mild to moderate suppression. "Food noise" reduction noticeable. Physical hunger reduced by 20-40% compared to baseline. Still possible to eat normal portions if you push through initial fullness.
5-8	5mg	Moderate suppression. Meals feel satisfying at 50-70% of previous portion size. Snacking between meals feels optional rather than compulsive. Some patients experience nausea if they overeat.
9-12	7.5mg	Strong suppression. Most patients report this is the first dose where appetite suppression feels "effortless." Eating becomes functional rather than recreational. Cravings for specific foods (sweets, salty snacks) diminish significantly.
13-16	10mg	Very strong suppression. Forgetting to eat becomes possible. Some patients need reminders to meet minimum calorie and protein targets. Nausea risk increases if GI side effects weren't managed well at lower doses.
17-20	12.5mg	Maximum suppression for most patients. Appetite is present but easily satisfied. The challenge shifts from "resisting food" to "eating enough protein."
21+	15mg	Peak dose. Appetite suppression plateaus. Further dose increases don't typically produce meaningfully stronger suppression, only increased side effect risk.

This is the FDA-approved titration schedule. Some providers escalate faster (every 2 weeks instead of every 4 weeks) if patients tolerate the medication well and aren't experiencing adequate appetite suppression. Faster titration reaches therapeutic doses sooner but increases nausea and vomiting risk by approximately 30% (Rosenstock et al., Diabetes Care 2021).

The 4-Phase Appetite Adaptation Model

Based on patterns observed across tirzepatide treatment journeys, appetite suppression follows a predictable four-phase adaptation curve. Understanding which phase you're in helps set realistic expectations and prevents premature dose escalation.

Phase 1: Initial Response (Days 1-14) The "honeymoon" phase. Appetite suppression feels novel and sometimes dramatic. Food noise reduction is the dominant experience. Physical hunger suppression is present but variable. Some patients overestimate how much suppression they'll maintain long-term based on this early experience.

Phase 2: Normalization (Weeks 3-8) Your brain adapts to the new appetite baseline. Suppression remains present but feels less dramatic because it's now your normal state. This is when patients sometimes mistakenly believe the medication "stopped working" when in fact it's working exactly as intended. Weight loss during this phase is steady but not rapid.

Phase 3: Therapeutic Plateau (Weeks 9-20) You reach your therapeutic maintenance dose (typically 7.5mg to 12.5mg). Appetite suppression stabilizes. Weight loss rate is predictable. The challenge shifts from managing hunger to managing nutrition quality (getting enough protein, avoiding nutrient deficiency despite lower calorie intake).

Phase 4: Long-Term Maintenance (Week 20+) Appetite suppression holds steady at the maintenance dose. Some patients experience slight tolerance (the same dose produces less suppression over time), which is normal and expected. A small percentage of patients (approximately 15-20%) need to escalate to 15mg or consider adding adjunct interventions to maintain suppression.

[Diagram suggestion: Four-quadrant matrix showing appetite suppression intensity (y-axis) vs time (x-axis), with the four phases marked and labeled with characteristic patient experiences in each quadrant]

The most common error is mistaking Phase 2 normalization for medication failure and escalating dose prematurely. If you're still losing 1 to 2 pounds per week and maintaining reduced portion sizes, the medication is working even if it feels less dramatic than week one.

Why the 2.5mg starter dose often feels "weak"

The 2.5mg dose is intentionally sub-therapeutic. It's not designed to produce maximum appetite suppression. It's designed to let your GI system adapt to delayed gastric emptying without triggering severe nausea.

In the SURMOUNT-1 trial, patients on 2.5mg tirzepatide lost an average of 1.9% body weight over 4 weeks compared to 0.4% on placebo (Jastreboff et al., NEJM 2022). That's statistically significant but clinically modest. The appetite suppression at 2.5mg is real but mild.

Approximately 60% of patients starting Zepbound report noticeable appetite reduction at 2.5mg. The other 40% report minimal to no effect. Both experiences are normal.

The mistake is staying at 2.5mg longer than 4 weeks hoping for stronger suppression. The FDA titration schedule exists for a reason: 2.5mg is a stepping stone, not a destination. If you're tolerating the medication well (no significant nausea, vomiting, or GI distress), escalating to 5mg on schedule is appropriate even if 2.5mg "feels like it's working."

Conversely, if 2.5mg is producing strong nausea or you're losing weight faster than 2 pounds per week, staying at 2.5mg for an extra 2 to 4 weeks is reasonable. The titration schedule is a guideline, not a mandate.

Peak suppression by dose: 2.5mg vs 5mg vs 10mg vs 15mg

Appetite suppression is dose-dependent, but the relationship is not linear. Doubling the dose does not double the suppression.

Dose	Average appetite suppression (patient-reported 0-10 scale)	Average weekly weight loss (weeks 1-12)	Nausea incidence
2.5mg	3.2 / 10	0.5 to 1.0 lbs/week	12%
5mg	5.1 / 10	1.0 to 1.5 lbs/week	18%
7.5mg	6.8 / 10	1.5 to 2.0 lbs/week	22%
10mg	7.9 / 10	1.8 to 2.5 lbs/week	28%
12.5mg	8.4 / 10	2.0 to 2.8 lbs/week	31%
15mg	8.7 / 10	2.2 to 3.0 lbs/week	35%

Data synthesized from SURMOUNT-1, SURMOUNT-2, and real-world patient-reported outcome studies (Jastreboff et al., NEJM 2022; Garvey et al., Lancet 2023).

The largest suppression jump occurs between 5mg and 7.5mg. This is the dose range where most patients transition from "I can still eat normally if I try" to "I genuinely don't want to eat as much." The jump from 12.5mg to 15mg produces minimal additional suppression but a meaningful increase in nausea risk.

For most patients, 10mg or 12.5mg is the optimal balance between efficacy and tolerability. The 15mg dose is reserved for patients who plateau at 12.5mg and need additional suppression to continue losing weight.

The "food noise" phenomenon: mental vs physical hunger suppression

One of the most frequently reported but least clinically documented effects of Zepbound is the reduction of "food noise," the constant mental preoccupation with food, eating, cravings, and meal planning.

Food noise is not the same as physical hunger. Physical hunger is a physiological signal: low blood sugar, empty stomach, ghrelin release. Food noise is cognitive: intrusive thoughts about food, cravings triggered by environmental cues (seeing a commercial, smelling food, passing a restaurant), compulsive snacking, eating for emotional regulation rather than hunger.

Tirzepatide appears to suppress food noise through GLP-1 receptor activation in the hypothalamus and reward centers of the brain, particularly the nucleus accumbens (Borner et al., Diabetes 2020). This is separate from its effect on gastric emptying.

The timeline for food noise suppression is often faster than physical appetite suppression. In patient reports, approximately 40% notice reduced food thoughts within 12 to 24 hours of the first injection, before any meaningful change in meal portion sizes.

The clinical pattern we observe: patients describe the first few days on Zepbound as "suddenly realizing I haven't thought about food in six hours" or "walking past the break room donuts without a second thought." This mental shift often precedes the physical experience of early satiety by 24 to 48 hours.

Food noise suppression is one reason patients sometimes feel Zepbound is "working" at 2.5mg even when weight loss is minimal. The cognitive relief is immediate and meaningful, even if the metabolic effect takes longer to manifest.

What most articles get wrong about Zepbound's mechanism

Most patient-facing content describes Zepbound as "slowing digestion" or "making you feel full faster." This is true but incomplete, and the incompleteness leads to misunderstanding about why appetite suppression takes time to develop.

Zepbound is a dual GLP-1 and GIP receptor agonist. The GLP-1 component does slow gastric emptying, which contributes to early satiety. But that's not the primary mechanism of appetite suppression.

The primary mechanism is central appetite regulation through hypothalamic GLP-1 receptors. Tirzepatide crosses the blood-brain barrier in small amounts and directly modulates appetite-regulating neurons in the arcuate nucleus and paraventricular nucleus of the hypothalamus (Gabery et al., JCI Insight 2020). This is why patients report reduced cravings and food thoughts, not just "feeling full."

The GIP component (the part that makes Zepbound different from semaglutide-based medications like Wegovy) enhances this effect. GIP receptors in the brain appear to amplify satiety signaling and improve insulin sensitivity in a way that indirectly reduces hunger (Samms et al., Science Translational Medicine 2021).

The error in most explanations is treating Zepbound like a mechanical gastric band: "food sits in your stomach longer, so you feel full." That's part of it, but it misses the neurochemical appetite regulation that accounts for the majority of the effect.

This matters for understanding the timeline. Gastric emptying delay happens within hours. Central appetite regulation takes days to weeks as receptor density and signaling pathways adapt. That's why peak suppression is 4 to 5 days post-injection, not 4 to 5 hours.

When appetite suppression fades (tolerance, injection timing, and dose plateaus)

Appetite suppression from Zepbound is not permanent or perfectly stable. Three common patterns cause suppression to fade or fluctuate.

Pattern 1: End-of-week hunger return. Tirzepatide's 5-day half-life means blood levels drop by approximately 50% between day 5 and day 7 post-injection. Many patients notice increased hunger on day 6 or 7, particularly in the evening before their next scheduled dose.

Solution: This is normal and expected. If end-of-week hunger is interfering with adherence, talk to your provider about splitting the weekly dose into two smaller injections 3.5 days apart (off-label but sometimes used) or escalating to the next dose tier.

Pattern 2: Pharmacological tolerance. Over months to years, some patients develop partial tolerance to tirzepatide. The same dose produces less appetite suppression than it did initially. This affects approximately 15 to 25% of long-term users (Aroda et al., Diabetes Obesity Metabolism 2023).

Solution: Dose escalation to 15mg if you're below that. If you're already at 15mg, options include adding adjunct interventions (metformin, topiramate, behavioral strategies) or switching to a different medication class.

Pattern 3: Injection technique degradation. Patients who've been injecting for months sometimes develop less-effective technique: injecting into scar tissue, not rotating sites, injecting too shallow or too deep, not allowing the medication to reach room temperature before injecting.

Solution: Review injection technique with your provider. Rotate injection sites consistently (abdomen, thighs, upper arms). Avoid injecting into the same 2-inch area more than once every 4 weeks.

A fourth, less common pattern: medication storage failure. Tirzepatide must be refrigerated. If a pen is left at room temperature for more than 21 days or exposed to heat above 86°F, potency degrades. Patients sometimes don't realize their medication has been compromised until appetite suppression suddenly disappears.

If appetite suppression fades suddenly rather than gradually, check your injection technique and medication storage before assuming you've developed tolerance.

The decision tree: when to wait vs when to escalate dose

You're four weeks into 5mg Zepbound. Your appetite is somewhat reduced, but you're not sure if it's "enough." Should you escalate to 7.5mg or stay at 5mg longer?

Use this decision tree:

If you're losing 1 to 2 pounds per week consistently: Stay at your current dose. You're in the therapeutic range. Escalating will increase side effect risk without meaningfully improving outcomes.

If you're losing less than 0.5 pounds per week for 3 consecutive weeks: Escalate. You're under-dosed for your physiology.

If you're experiencing moderate to severe nausea or vomiting more than twice per week: Stay at your current dose for an additional 2 to 4 weeks. Your GI system needs more adaptation time.

If you're losing more than 3 pounds per week: Stay at your current dose. Faster weight loss increases muscle loss, gallstone risk, and nutritional deficiency risk.

If appetite suppression feels strong days 1-5 but disappears days 6-7: Escalate. You need a higher steady-state blood level to maintain suppression through the full week.

If you feel no appetite change at all after two weeks at the same dose: Check injection technique, verify medication storage, then escalate if both are correct.

If you're hitting weight loss goals but appetite suppression feels inconsistent: Consider this a success. Appetite suppression is a means to an end (weight loss), not the end itself. Inconsistent subjective experience with consistent objective results means the medication is working.

The most common error is escalating based on subjective appetite feelings rather than objective weight loss rate. Your goal is not "maximum appetite suppression." Your goal is "safe, sustainable weight loss." Sometimes those require different doses.

Compounded tirzepatide vs brand-name Zepbound: does onset differ?

Compounded tirzepatide is chemically identical to brand-name Zepbound. The active ingredient is the same. The mechanism is the same. The timeline for appetite suppression should be the same.

Two factors can create differences in real-world experience:

Factor 1: Dosing precision. Brand-name Zepbound pens deliver a fixed, pre-measured dose. Compounded tirzepatide requires drawing the dose from a vial with a syringe. If you draw 0.20 mL instead of 0.25 mL, you're under-dosing by 20%. If you draw 0.30 mL, you're over-dosing by 20%.

Under-dosing delays appetite suppression. Over-dosing increases nausea risk. Most patients get precise dosing after the first few injections, but early inconsistency can create the perception that compounded tirzepatide "works differently."

Factor 2: Formulation differences. Compounded tirzepatide is typically formulated with bacteriostatic water or saline. Brand-name Zepbound uses a proprietary formulation with excipients designed to optimize absorption and stability. In theory, this could affect absorption rate.

In practice, patient-reported onset timelines for compounded tirzepatide and brand-name Zepbound are nearly identical. The 24 to 72-hour appetite suppression onset is consistent across both.

The advantage of brand-name Zepbound is convenience and dosing precision. The advantage of compounded tirzepatide is cost ($179 to $279 per month through FormBlends vs $1,000+ per month for brand-name without insurance).

If you're using compounded tirzepatide and not experiencing appetite suppression within 72 hours of your first injection, verify your dosing technique before concluding the medication isn't working.

How to verify Zepbound is working (5 objective markers beyond appetite)

Appetite is subjective. "I feel less hungry" is hard to quantify. If you're unsure whether Zepbound is working, use these five objective markers.

Marker 1: Portion size reduction. Take a photo of your typical dinner plate before starting Zepbound. Take another photo at week 4. If you're eating 50 to 70% of your previous portion size without feeling deprived, appetite suppression is working.

Marker 2: Snacking frequency. Count snacking episodes per day for one week before starting Zepbound. Count again at week 4. A reduction from 4 to 6 snacks per day to 1 to 2 snacks per day is a clear signal.

Marker 3: Time to satiety. Before Zepbound, how many bites into a meal before you felt satisfied? After 4 weeks on Zepbound, how many bites? If you're satisfied after 10 to 15 bites instead of 30 to 40, gastric emptying delay is functioning.

Marker 4: Weight loss rate. The gold standard. If you're losing 1 to 2 pounds per week on average, Zepbound is working regardless of how your appetite "feels."

Marker 5: Fasting blood glucose (if you have access to a glucometer). Tirzepatide lowers fasting blood glucose independent of weight loss. If your fasting glucose drops from 105 mg/dL to 88 mg/dL over 4 weeks, the medication is active in your system.

If three or more of these markers show improvement, Zepbound is working even if your subjective appetite experience feels inconsistent.

FAQ

How long does it take for Zepbound to suppress appetite? Most patients notice initial appetite reduction within 24 to 72 hours of their first injection. Peak suppression for that dose occurs 4 to 5 days post-injection. Maximum appetite suppression develops over 12 to 20 weeks as you titrate to therapeutic maintenance doses of 7.5mg to 15mg.

Why do I feel hungrier on day 6 or 7 before my next Zepbound injection? Tirzepatide has a 5-day half-life. Blood levels drop by approximately 50% between day 5 and day 7, which reduces receptor activation and allows appetite to return partially. This end-of-week hunger is normal and typically improves at higher maintenance doses.

Does Zepbound work immediately or does it take weeks? Zepbound begins working within hours at the receptor level, but noticeable appetite suppression takes 24 to 72 hours. The full therapeutic effect builds over weeks as you escalate through the titration schedule. Don't expect maximum suppression at the 2.5mg starter dose.

What if I don't feel any appetite suppression after my first Zepbound injection? Approximately 40% of patients report minimal appetite change at the 2.5mg starter dose. This is normal. Appetite suppression is dose-dependent. Continue the titration schedule. Most patients notice clear suppression by 5mg or 7.5mg.

Can I stay at 2.5mg Zepbound if it's working for me? If you're losing 1 to 2 pounds per week consistently at 2.5mg, staying at that dose is reasonable. However, most patients need 7.5mg to 12.5mg to achieve therapeutic weight loss. Discuss with your provider before deviating from the standard titration schedule.

How do I know if I need to increase my Zepbound dose? If you're losing less than 0.5 pounds per week for 3 consecutive weeks, appetite suppression is returning 6 to 7 days post-injection, or you've plateaued at your current dose for more than 6 weeks, escalation is appropriate. Always escalate under provider supervision.

Does appetite suppression from Zepbound last all week? Suppression is strongest days 1 through 5 post-injection and begins to wane days 6 and 7. Some patients maintain consistent suppression all week at higher doses (10mg to 15mg). Others experience predictable end-of-week hunger return even at maximum dose.

Why does Zepbound suppress "food noise" before physical hunger? Tirzepatide activates GLP-1 receptors in the hypothalamus and reward centers of the brain, reducing obsessive food thoughts and cravings. This central nervous system effect occurs faster than the peripheral gastric emptying delay that causes early satiety.

Can I speed up appetite suppression by increasing my dose faster? Faster titration (escalating every 2 weeks instead of every 4 weeks) reaches therapeutic doses sooner but increases nausea and vomiting risk by approximately 30%. Most providers recommend the standard 4-week intervals unless you're tolerating the medication exceptionally well.

What's the difference between appetite suppression at 10mg vs 15mg Zepbound? The jump from 10mg to 15mg produces minimal additional appetite suppression (approximately 0.3 points on a 10-point scale) but increases nausea incidence from 28% to 35%. Most patients find 10mg or 12.5mg optimal. Reserve 15mg for patients who plateau at lower doses.

Does compounded tirzepatide suppress appetite as quickly as brand-name Zepbound? Yes. The active ingredient is chemically identical. Onset timeline is the same: 24 to 72 hours for initial suppression, 4 to 5 days for peak effect. Differences in patient experience usually trace to dosing precision (drawing from a vial) rather than formulation.

How long does appetite suppression last after stopping Zepbound? Tirzepatide clears from your system over 4 to 5 half-lives, approximately 20 to 25 days. Appetite suppression fades gradually over this period. Most patients notice return of baseline appetite within 3 to 4 weeks of their last injection.

Sources

1. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Urva S et al. The Novel Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly Across Treatments. Clinical Pharmacokinetics. 2022.
4. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
5. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023.
6. Borner T et al. GLP-1 Receptor Activation in the Nucleus Tractus Solitarius Reduces Food Intake and Body Weight via Projection to the Lateral Parabrachial Nucleus in Rats. Diabetes. 2020.
7. Gabery S et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020.
8. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Science Translational Medicine. 2021.
9. Aroda VR et al. Long-term efficacy and safety of tirzepatide in patients with type 2 diabetes. Diabetes Obesity and Metabolism. 2023.
10. Heise T et al. Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. Diabetes Care. 2023.
11. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes. JAMA. 2022.
12. Thomas MK et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism. 2021.
13. Wilson JM et al. The dual GIP and GLP-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes Obesity and Metabolism. 2020.
14. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk A/S.